Araştırma Makalesi

Increased ascites natural killer cells in patients with chronic hepatitis B cirrhosis using lamivudine: A pilot study

Cilt: 18 Sayı: 3 25 Aralık 2019
  • İbrahim Köker *
  • Belkıs Ünsal
PDF İndir
EN TR

Increased ascites natural killer cells in patients with chronic hepatitis B cirrhosis using lamivudine: A pilot study

Öz

Background and Aims: Natural killer cells play a direct role in liver injury and fibrogenic response. Peripheral blood natural killer cells have been studied widely in chronic liver diseases. We aimed to evaluate the ascites natural killer cell frequency and its significance in chronic hepatitis B related cirrhosis. Materials and Methods: Overall, 30 patients [23 males] with decompensated chronic hepatitis B cirrhosis with ascites were included. Patients with a recent ascites infection history and other etiologic factors besides chronic hepatitis B infection were excluded. After defining the demographic characteristics of the cases, we divided patients according to their Child-Turcotte-Pugh classification scores into two groups, and their natural killer (CD3−/CD16+/CD56+) cell frequencies in peripheral blood and ascites were studied using flow cytometry. Finally, we compared the natural killer cell frequencies in peripheral blood and ascites between the Child-Turcotte-Pugh classification groups based on lamivudine use. Results: Median lamivudine usage duration was 60 months, interquartile range 18.7–93 months in Child-Turcotte-Pugh B and 7.5 months, interquartile range 2.2–21 months in Child-Turcotte-Pugh C (p = 0.053). Ascites natural killer cells were significantly increased in lamivudine users of Child-Turcotte-Pugh B (p = 0.049), whereas no change was observed in peripheral blood - natural killer frequency in patients using lamivudine in the Child-Turcotte-Pugh B and C groups (p = 0.574 and p = 0.174, respectively). Conclusion: Long-term lamivudine use might have increased the ascites natural killer frequency, whereas no change was observed in the peripheral blood - natural killer cell frequency in patients with chronic hepatitis B cirrhosis, suggesting a potential role of antivirals in ascites natural killer cell response.

Anahtar Kelimeler

Kaynakça

  1. 1- Lin J, Wu JF, Zhang Q, Zhang HW, Cao GW. Virus-related liver cirrhosis: molecular basis and therapeutic options. World J Gastroenterol 2014;20:6457-69.
  2. 2- Gao B, Radaeva S. Natural killer and natural killer T cells in liver fibrosis. Biochim Biophys Acta 2013; 1832:1061-9.
  3. 3- Melhem A, Muhanna N, Bishara A, et al. Antifibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 2006;45:60-71.
  4. 4- Notas G, Kisseleva T, Brenner D. NK and NKT cells in liver injury and fibrosis. Clin Immonol 2009;130:16-26.
  5. 5- Lv J, Jin Q, Sun H, et al. Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic hepatitis B virus infected patients. Mediators Inflamm 2012;2012:804043.
  6. 6- Tjwa ET, van Oord GW, Biesta PJ, et al. Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B virus infection. J Virol 2012;86:4102-9.
  7. 7- Oliviero B, Varchetta S, Paudice E, et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009;137:1151-60.
  8. 8- Scott-Algara D, Mancini-Bourgine M, Fontaine H, Pol S, Michel ML. Changes to the natural killer cell reportoire after therapeutic hepatitis B DNA vaccination. PLoS One 2010;18:e8761.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi

Bölüm

Araştırma Makalesi

Yazarlar

İbrahim Köker * Bu kişi benim
0000-0002-4513-6927
Türkiye

Yayımlanma Tarihi

25 Aralık 2019

Gönderilme Tarihi

31 Mayıs 2019

Kabul Tarihi

7 Aralık 2019

Yayımlandığı Sayı

Yıl 2019 Cilt: 18 Sayı: 3

Kaynak Göster

APA
Köker, İ., & Ünsal, B. (2019). Increased ascites natural killer cells in patients with chronic hepatitis B cirrhosis using lamivudine: A pilot study. Akademik Gastroenteroloji Dergisi, 18(3), 80-86. https://doi.org/10.17941/agd.676970
AMA
1.Köker İ, Ünsal B. Increased ascites natural killer cells in patients with chronic hepatitis B cirrhosis using lamivudine: A pilot study. Akademik Gastroenteroloji Dergisi. 2019;18(3):80-86. doi:10.17941/agd.676970
Chicago
Köker, İbrahim, ve Belkıs Ünsal. 2019. “Increased ascites natural killer cells in patients with chronic hepatitis B cirrhosis using lamivudine: A pilot study”. Akademik Gastroenteroloji Dergisi 18 (3): 80-86. https://doi.org/10.17941/agd.676970.
EndNote
Köker İ, Ünsal B (01 Aralık 2019) Increased ascites natural killer cells in patients with chronic hepatitis B cirrhosis using lamivudine: A pilot study. Akademik Gastroenteroloji Dergisi 18 3 80–86.
IEEE
[1]İ. Köker ve B. Ünsal, “Increased ascites natural killer cells in patients with chronic hepatitis B cirrhosis using lamivudine: A pilot study”, Akademik Gastroenteroloji Dergisi, c. 18, sy 3, ss. 80–86, Ara. 2019, doi: 10.17941/agd.676970.
ISNAD
Köker, İbrahim - Ünsal, Belkıs. “Increased ascites natural killer cells in patients with chronic hepatitis B cirrhosis using lamivudine: A pilot study”. Akademik Gastroenteroloji Dergisi 18/3 (01 Aralık 2019): 80-86. https://doi.org/10.17941/agd.676970.
JAMA
1.Köker İ, Ünsal B. Increased ascites natural killer cells in patients with chronic hepatitis B cirrhosis using lamivudine: A pilot study. Akademik Gastroenteroloji Dergisi. 2019;18:80–86.
MLA
Köker, İbrahim, ve Belkıs Ünsal. “Increased ascites natural killer cells in patients with chronic hepatitis B cirrhosis using lamivudine: A pilot study”. Akademik Gastroenteroloji Dergisi, c. 18, sy 3, Aralık 2019, ss. 80-86, doi:10.17941/agd.676970.
Vancouver
1.İbrahim Köker, Belkıs Ünsal. Increased ascites natural killer cells in patients with chronic hepatitis B cirrhosis using lamivudine: A pilot study. Akademik Gastroenteroloji Dergisi. 01 Aralık 2019;18(3):80-6. doi:10.17941/agd.676970